ALDX Q2 2025 Earnings — Aldeyra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALDXAldeyra Therapeutics, Inc.

$318M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$10M

Net Income

-$10M

EPS (Diluted)

$-0.16

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$196,565

Balance Sheet

Total Assets

$85M

Total Liabilities

$30M

Stockholders' Equity

$55M

Cash & Equivalents

$41M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$10M	-$18M	+43.5%
Net Income	-$10M	-$17M	+42.0%